Forbion announces Amgen agreement to acquire portfolio company Biovex for up to US$1 billion
Acquisition of a Potential, First-in-Class Cancer Therapeutic in Late-Stage Clinical Trials for the Treatment of Advanced Melanoma and Head and Neck Cancer
26-Jan-2011 -
Forbion Capital Partners announced that Amgen and Biovex, Inc. have entered into a definitive acquisition agreement where Amgen has agreed to acquire BioVex Group, Inc., a privately held biotechnology company that has two biologics in clinical development, including BioVex’s lead product ...
Amgen